P1-IS-32 Targeted Alpha Therapy for Ovarian Cancer : Development and Characterization of Bismuth-213 (213 Bi) labeled uPAR-selective Radioligands
スポンサーリンク
概要
- 論文の詳細を見る
- 社団法人 日本産科婦人科学会の論文
- 2007-02-01
著者
-
Sato Sumito
Clinical Research Unit Department Of Obstetrics And Gynecology
-
Seidl Christof
Departments of Nuclear Medicine, Technical University Munchen
-
Knor Sebastian
Department Chemie, Lehrstuhl II fur Organische Chemie, Technical University Munchen
-
Huber Timo
Department Chemie, Lehrstuhl II fur Organische Chemie, Technical University Munchen
-
Kessler Horst
Department Chemie, Lehrstuhl II fur Organische Chemie, Technical University Munchen
-
Senekowitsch-Schmidtke Reingard
Departments of Nuclear Medicine, Technical University Munchen
-
Magdolen Viktor
Clinical Research Unit, Department of Obstetrics and Gynecology
-
Huber Timo
Department Chemie Lehrstuhl Ii Fur Organische Chemie Technical University Munchen
-
Kessler Horst
Department Chemie Lehrstuhl Ii Fur Organische Chemie Technical University Munchen
-
Knor Sebastian
Department Chemie Lehrstuhl Ii Fur Organische Chemie Technical University Munchen
-
Seidl Christof
Departments Of Nuclear Medicine Technical University Munchen
-
Seidl Christof
Department Of Nuclear Medicine Technische Universitat Munchen
-
Magdolen Viktor
Clinical Research Unit Department Of Obstetrics And Gynecology
-
Senekowitsch-schmidtke Reingard
Departments Of Nuclear Medicine Technical University Munchen
-
Senekowitsch-schmidtke Reingard
Department Of Nuclear Medicine Technische Universitat Munchen
関連論文
- P1-IS-32 Targeted Alpha Therapy for Ovarian Cancer : Development and Characterization of Bismuth-213 (213 Bi) labeled uPAR-selective Radioligands
- ^Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice